Reasons for resistance to aspirin in cardiovascular disease.
Szczeklik
A
A
Musiał
J
J
Undas
A
A
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects / Q000235:genetics; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy; D039661:Integrin beta3 / Q000235:genetics; D015539:Platelet Activation / Q000187:drug effects / Q000235:genetics; D011110:Polymorphism, Genetic; D012306:Risk; D055502:Secondary Prevention; D017211:Treatment Failure
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D039661:Integrin beta3; D001241:Aspirin